JP2002520282A5 - - Google Patents

Download PDF

Info

Publication number
JP2002520282A5
JP2002520282A5 JP2000558815A JP2000558815A JP2002520282A5 JP 2002520282 A5 JP2002520282 A5 JP 2002520282A5 JP 2000558815 A JP2000558815 A JP 2000558815A JP 2000558815 A JP2000558815 A JP 2000558815A JP 2002520282 A5 JP2002520282 A5 JP 2002520282A5
Authority
JP
Japan
Prior art keywords
composition
hydrogen
group
lower alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000558815A
Other languages
English (en)
Other versions
JP2002520282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/015501 external-priority patent/WO2000002555A1/en
Publication of JP2002520282A publication Critical patent/JP2002520282A/ja
Publication of JP2002520282A5 publication Critical patent/JP2002520282A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 患者における慢性リンパ性白血病(CLL)の処置のための組成物であって、該組成物は、以下の式Iのインドールまたはカルバゾール誘導体あるいはその薬学的に受容可能な塩の治療的有効量を含み
【化1】
Figure 2002520282
ここで、R1は、水素、低級アルキル、低級アルケニル、低級アルキニル、アルコキシ低級アルキル、低級シクロアルキル、フェニル、ベンジルおよび2−チエニルからなる群から選択され;R2およびR3は、同一であるかまたは異なり、そして各々は、水素および低級アルキルからなる群から選択され;R4およびR5は、同一であるかまたは異なり、そして各々は、水素、低級アルキル、−NH2、−NHCHO、−NHCONH2、=NW、オキソ、−OHおよび−OCH3からなる群から選択され、ここでWは、ヒドロキシ、アルコキシ、アリールオキシ、カルボキシアルキルオキシ、アリールアミノまたはアルキルスルホニルアミノであり;R6は、水素、低級アルキル、低級アルケニル、低級アルキニル、トリフルオロメチル、ヒドロキシ、低級アルコキシ、トリフルオロ低級アルコキシ、ベンジルオキシ、アラルオキシ、低級アルカノイルオキシ、アシル、アミノ、ニトロ、シアノ、アルキルイミド、ハロ、メルカプト、低級アルキルチオ、アルキルスルフィニル、アルキルスルホニル、アルキルスルホンアミドおよびスルファモイルからなる群から選択され;R7は、水素、低級アルキルおよび低級アルケニルからなる群から選択され;Xは、炭素、オキシ、およびチオからなる群から選択され;Yは、カルボニル、
【化2】
Figure 2002520282
からなる群から選択され、ここで、R8、R9、R10、R11、R12およびR13の各々は、水素または低級アルキルであり;そしてZは、ヒドロキシ、低級アルコキシ、アミノ、低級アルキルアミノ、ジ(低級)アルキルアミノおよびフェニルアミノからなる群から選択される、組成物
【請求項2】 前記インドールまたはカルバゾール誘導体がエトドラクである、請求項1に記載の組成物
【請求項3】 請求項2に記載の組成物であって、ここで、1日当たり前記患者の体重1kg当たり約1.0mg〜500mgのエトドラクの用量で投与に適する組成物
【請求項4】 前記エトドラク経口投与に適する、請求項3に記載の組成物
【請求項5】 請求項1に記載の組成物であって、ここで、前記治療的有効量のインドールまたはカルバゾール化合物が、前記患者における白血病性リンパ球のレベルを減少させるに十分である、組成物
【請求項6】 請求項1に記載の組成物であって、ここで、前記インドールまたはカルバゾール化合物が、薬学的組成物の形態でる、組成物
【請求項7】 請求項6に記載の組成物であって、ここで、前記薬学的組成物がさらに、薬学的に受容可能なキャリアまたは希釈液を含む、組成物
【請求項8】 慢性リンパ性白血病の処置のための医薬の製造における、請求項1に記載の化合物の使用。
JP2000558815A 1998-07-09 1999-07-08 慢性リンパ性白血病の処置のための方法および組成物 Pending JP2002520282A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9246698P 1998-07-09 1998-07-09
US60/092,466 1998-07-09
US9487898P 1998-07-29 1998-07-29
US60/094,878 1998-07-29
PCT/US1999/015501 WO2000002555A1 (en) 1998-07-09 1999-07-08 Methods and compositions for the treatment of chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
JP2002520282A JP2002520282A (ja) 2002-07-09
JP2002520282A5 true JP2002520282A5 (ja) 2006-10-05

Family

ID=26785713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000558815A Pending JP2002520282A (ja) 1998-07-09 1999-07-08 慢性リンパ性白血病の処置のための方法および組成物

Country Status (12)

Country Link
US (3) US6573292B1 (ja)
EP (1) EP1104297B8 (ja)
JP (1) JP2002520282A (ja)
AT (1) ATE315392T1 (ja)
AU (1) AU767586B2 (ja)
CA (1) CA2336932A1 (ja)
DE (1) DE69929440T2 (ja)
DK (1) DK1104297T3 (ja)
ES (1) ES2255287T3 (ja)
NZ (1) NZ509376A (ja)
PT (1) PT1104297E (ja)
WO (1) WO2000002555A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1104297T3 (da) * 1998-07-09 2006-05-29 Cephalon Inc Sammensætninger til behandling af kronisk lymfocytisk leukæmi
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7361680B2 (en) 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US7211599B2 (en) 2002-09-19 2007-05-01 The Regents Of The University Of California Use of etodolac to treat hyperplasia
WO2005033112A2 (en) * 2003-10-02 2005-04-14 Cephalon, Inc. Substituted indole derivatives
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
RU2474612C2 (ru) * 2008-05-20 2013-02-10 Инкурон ЛЛК Индуцирование гибели клеток путем ингибирования адаптивного теплового шокового ответа
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
WO2010083276A1 (en) * 2009-01-15 2010-07-22 Cephalon, Inc. Novel forms of bendamustine free base
JP2013537552A (ja) 2010-08-18 2013-10-03 デル マー ファーマスーティカルズ ジアンヒドロガラクチトール及びジアセチルジアンヒドロガラクチトール等の置換ヘキシトールを含む準最適に投与された化合物の治療的有効性を改良するための組成物及び方法
WO2014081405A2 (en) 2011-08-17 2014-05-30 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
KR20220137154A (ko) 2012-01-20 2022-10-11 데니스 엠. 브라운 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9814693B2 (en) 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
KR20150034209A (ko) 2012-06-26 2015-04-02 델 마 파마슈티컬스 인코포레이티드 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
JP2017513933A (ja) 2014-04-06 2017-06-01 インクロン, リミテッド ライアビリティー カンパニー クラキシンとの併用療法
CN109689045A (zh) 2016-05-04 2019-04-26 因美制药公司 大麻素的局部制剂在治疗大疱性表皮松解症和相关结缔组织病症中的用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1071897B (ja) 1957-12-19 1959-12-24
US3843480A (en) 1963-08-28 1974-10-22 D Dreher Dry dry transfer
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3974179A (en) 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3843681A (en) 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3839178A (en) * 1972-10-05 1974-10-01 Gen Electric Potentiometric oxygen sensor
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS5777617A (en) 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4542013A (en) 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
US4460562A (en) 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4542012A (en) 1982-07-02 1985-09-17 Minnesota Mining And Manufacturing Company Film-forming composition containing an antimicrobial agent and methods
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
IT1153909B (it) 1982-12-17 1987-01-21 Sogimi Srl Polimeri reattivi per la cura di affezioni cutanee
GB8317576D0 (en) 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4585877A (en) 1985-05-06 1986-04-29 American Home Products Corporation Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4686213A (en) * 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US4748252A (en) 1986-08-15 1988-05-31 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
CA2131992A1 (en) 1992-03-13 1993-09-16 James W. Young Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5599946A (en) 1995-05-30 1997-02-04 Teva Pharmaceutical Industries Ltd. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation
WO1997003667A1 (en) * 1995-07-19 1997-02-06 Merck & Co., Inc. Method of treating colonic adenomas
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US6255347B1 (en) 1996-06-21 2001-07-03 Advanced Research And Technology Institute Methods and compositions comprising R-ibuprofen
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
AU4043397A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Pyranoindole and carbazole inhibitors of cox-2
CA2270887C (en) * 1996-11-05 2006-03-21 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
DK1104297T3 (da) * 1998-07-09 2006-05-29 Cephalon Inc Sammensætninger til behandling af kronisk lymfocytisk leukæmi
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
AU2001283224B2 (en) 2000-08-09 2007-06-28 The Regents Of The University Of California Indole compounds useful for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2002520282A5 (ja)
US20050261356A1 (en) Methods and compositions for the treatment of chronic lymphocytic leukemia
JP2002519425A5 (ja)
JP2004509061A5 (ja)
MY125662A (en) Pharmaceutical formulations containing darifenacin
RU2003107921A (ru) Селективные циклопептиды
JP2001512103A5 (ja)
JP2008514732A5 (ja)
JP2002510633A5 (ja)
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
JP2001526218A5 (ja)
JP2002543144A5 (ja)
MY118156A (en) Oral compositions of levosimendan.
JP2003534246A5 (ja)
JP2003502367A5 (ja)
JP2002522501A5 (ja)
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
JP2002506864A5 (ja)
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
JP2001519413A5 (ja)
JP2002526550A5 (ja)
TW200517127A (en) Novel composition
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
JP2003534318A5 (ja)